Financing ·
Lakewood-Amedex redeems all Series C Preferred Stock for $1.27M, eliminating dilution risk
LABTLakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics completed the redemption of 127,097 outstanding shares of its Series C Convertible Preferred Stock from Shakawe Capital LLC for an aggregate cash price of $1,270,970. The transaction was funded using available cash on hand and closed on November 4, 2026. Following the redemption, no preferred stock remains outstanding, eliminating potential future dilution to common shareholders and removing associated financing restrictions. This action simplifies the company's capital structure and provides greater financial flexibility for its development programs. Lakewood-Amedex Biotherapeutics is a clinical-stage biotechnology company developing novel antimicrobials called Bisphosphocins to treat infectious diseases.